Table 1 Classification of CK2 inhibitors

Class of the inhibitor	Subclass	Representative compounds	References
ATP-competitive inhibitors	Polyhalogenated benzimidazoles and benzotriazoles	TBB	³⁰⁷
		TDB	³⁰⁸
		DMAT	³⁰⁹
	Flavonoids	Quercetin	³¹⁰
	Coumarins	Ellagic acid	³¹¹
	Anthraquinones	Quinalizarin	³¹²
	Pyrazolotriazines	Compound 9e	²⁸
	SRPIN803 derivatives	Compound 4	³¹³
	Carboxyl acid derivatives	TBCA	³¹⁴
		IQA	³¹⁰
		CX-4945	³¹⁵
		CX-5011	²⁷
	Triazol bromoguaiacol derivatives	GO289	²⁹
Peptide-competitive inhibitors		CIGB-300	²⁶
Allosteric inhibitors	α/β interface targeting	Pc	²⁴
Allosteric inhibitors		POMs	²⁵
Bi-substrate inhibitors		ARCs	²²
Bi-substrate inhibitors		K137-E4	²³
Multi-target inhibitors	CK2 and HDAC targeting		³¹⁶
Multi-target inhibitors	CX-4945 + CisPt		³¹⁷

Compounds in human clinical trials are in bold
TBB 4,5,6,7-tetrabromo-2-azabenzimidazole, TDB 1-(β-D-2′-deoxyribofuranosyl)-4,5,6,7-tetrabromo-1H-benzimidazole, DMAT 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole, TBCA tetrabromo-cinnamic acid, IQA [5-oxo-5,6-dihydro-indolo(1,2-a)quinazolin-7-yl]acetic acid, POMs polyoxometalates, HDAC histone deacetylase, CisPt cisplatin

Quick links

Search